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Identity 
Other names: Bfk, C1orf178, FLJ22588 
HGNC (Hugo): BCL2L15 
Location: 1p13.2 
Local order: Centromere to telomere. 
DNA/RNA 
Description 
The BCl2L15 gene has a total length of 10734 nt and 
consists of 4 exons and 3 intervening introns (Coultas 
et al., 2003). The organization of the BCL2L15 gene, 
with the BH3 domain located on a single exon (exon 2) 
and the BH2 domain split between two exons (exons 3 
and 4), is similar to that of other BCL2 family 
members, including BCL2, BCL2L1 (BCLX), BAX, 
and BAK1 (BAK) (Petros et al., 2004). 
 
Figure 1. Schematic representation of the BCL2L15 gene. Exons are shown as boxes and introns as connecting lines. The coding 
sequences are highlighted as red, while 5' and 3' untranslated regions (UTRs) are shown in white. Numbers inside or outside boxes 
indicate lengths (nt) of exons and introns, respectively, while numbers in parentheses indicate lengths (aa) of protein isoforms. Arrows (↓) 
show the position of the start codons (ATG) and asterisks (*) denote the position of the stop codons (TGA). Question marks (?) indicate 
that the full-length sequence was not determined. Roman numerals indicate intron phases. The intron phase refers to the location of the 
intron within the codon; I denotes that the intron occurs after the first nucleotide of the codon, II denotes that the intron occurs after the 
second nucleotide, and 0 means that the intron occurs between distinct codons. The figure is drawn to scale, except for the introns 
containing the (//) symbol. 
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Transcription 
The BCL2L15 gene is subjected to alternative splicing, 
generating four splice variants, three of which are 
considered as coding transcripts. Each coding splice 
variant consists of a distinctive exon combination and 
encodes a different protein isoform. The predominant 
transcript, consisting of 4973 nt, includes all 4 exons 
and encodes isoform a. The second transcript, predicted 
to encode isoform b, contains exons 1, 2 and 4. The 
deletion of exon 3 does not result in frameshifting. The 
third transcript, putatively encoding isoform d, consists 
of exons 1 and 4. The lack of exons 2 and 3 shifts the 
open reading frame. 
As aforementioned, except for alternatively spliced 
BCL2L15 coding variants, another noncoding 
transcript has also been identified. This one is 
composed of exons 1, 3 and 4, and was initially 
considered to encode isoform c. Nonetheless, this 
transcript is a nonsense-mediated mRNA decay (NMD) 
candidate, since deletion of exon 2 generates a 
premature translation termination codon in exon 3. 
Interestingly, transcription of all BCL2L15 
alternatively spliced variants was noticed only in colon, 
while the full-length transcript was also detected in 
stomach, rectum, small intestine, cerebellum, testis and 
uterus (Dempsey et al., 2005). Moreover, despite the 
fact that a p53 consensus binding site was identifid 
upstream of the transcription initiation site of 
BCL2L15, this gene does not constitute a 
transcriptional target of p53 (TP53) (Ozören et al.,
2009). 
Pseudogene 




The full-length BCL2L15 isoform (isoform a) is the 
predominant one. It consists of 163 amino acid residues 
and has a molecular mass of 17.7 kDa. BCL2L15 
isoform a contains a BH3 and a BH2 domain, but no 
BH1, BH4 or hydrophobic tail (Coultas et al., 2003). 
Isoform a is the predominant BCL2L15 isoform and the 
only one that has been in vivo detected so far. 
The amino acid sequences of isoforms b and c are 
deduced from the mRNA sequences of the BCL2L15 
alternatively spliced variants, and remain to be 
experimentally validated and in vivo detected. Isoform 
b is a putative BH3-only protein of 88 amino acid 
residues, with a calculated molecular mass of 9.6 kDa. 
This isoform shares the same termini with BCL2L15 
isoform; still, it bears no BH2 domain. Finally, isoform 
d is the smallest predicted BCL2L15 isoform. This 
protein of 56 amino acid residues, with a molecular 
mass of 6.3 kDa, possesses no BCL2-homology (BH) 
domains (Dempsey et al., 2005). 
The N-terminal region of all BCL2L15 isoforms shares 
partial homology (ECIxNxLxxxFL peptide) with BID 
(Dempsey et al., 2005), a BH3-only proapoptotic 
member of the BCL2 family (Lomonosova and 
Chinnadurai, 2008). Moreover, all BCL2L15 isoforms 
contain a caspase-3/caspase-7 cleavage site (DEVD 
peptide) (Dempsey et al., 2005). This tetrapeptide, 
corresponding to amino acid residues 38-41, is 
responsible for the removal of an N-terminal peptide 
fragment and the subsequent activation of the 
predominant BCL2L15 isoform, at least during DNA 
damage-induced apoptosis (Dempsey et al., 2005; 
Ozören et al., 2009). 
 
Figure 2. Alignment of amino acid sequences and structural motifs of the BC2L15 protein isoforms. Light blue and pink denote 
the BH2 and BH3 domains, respectively, while the amino acid residues constituting the consensus sequence of each BCL2 homology 
domain are shown in dark blue and red color. Yellow highlights the site of caspase-3/7 cleavage (DEVD tetrapeptide), which is 
considered to be critical for the activation of the proapoptotic action of BCL2L15, at least in certain cell types and/or after certain stimuli, 
including DNA damage-induced apoptosis. Finally, light green highlights the ECIxNxLxxxFL peptide, which BCL2L15 isoforms share with 
BID; its conserved amino acid residues are shown in dark green. 
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Expression 
The BCL2L15 protein is mainly expressed in tissues of 
the gastrointestinal tract, including the stomach, small 
intestine, colon and rectum (Dempsey et al., 2005; 
Ozören et al., 2009). The full-length isoform has also 
been detected in several colorectal cancer cell lines, 
such as SW480, HT-29 and HCT116 (Ozören et al., 
2009). 
Localisation 
The BCL2L15 protein is localized to the cytoplasm of 
intestinal epithelial cells (Ozören et al., 2009). It does 
not possess any signal peptide or C-terminal membrane 
anchor and, consequently, it is not associated withany 
cellular organelles (Coultas et al., 2003; Ozören et al., 
2009), unlike other members of the BCL2 family 
(Thomadaki and Scorilas, 2006). The localization of 
the cleaved BCL2L15 has not been elucidated yet. 
Function 
BCL2L15 is a weakly proapoptotic member of the 
BCL2 family (Coultas et al., 2003; Dempsey et al., 
2005; Pujianto et al., 2007). When overexpressed, the 
full-length BCL2L15 isoform interacts with BCL2L1 
long isoform (BCLXL) and BCL2L2 (BCLW), but not 
with BCL2 or BAD, as revealed by co-
immunoprecipitation experiments (Ozören et al., 2009). 
Furthermore, it has been speculated that BCL2L15 acts 
most probably as an amplifier of the apoptotic signal 
rather than a trigger of programmed cell death (Pujianto 
et al., 2007; Ozören et al., 2009). 
Given the weak proapoptotic activity of BCL2L15, it 
was initially suggested that the full-length BCL2L15 
could represent the latent form of a potent BH3-only 
protein exerting its proapoptotic action once activated 
through proteolytic cleavage (Coultas et al., 2003), like 
caspase-8 cleavage of BID (Li et al., 1998; Luo et al., 
1998), at least in certain cell types or after certain 
stimuli. In support of this notion, it was shown tha  
BCL2L15 becomes cleaved in a caspase-dependent 
manner during DNA damage-induced apoptosis and 
that truncated BCL2L15 (~13 kDa), corresponding to 
the part of protein downstream of the caspase-3/7 
cleavage site, is capable of inducing apoptosis in 
HCT116 cells, in contrast to the full-length BCL2L15 
isoform, which seems to be incapable of inducing 
apoptosis in HCT116 or SW480 colorectal cancer cells. 
Interestingly, the ability of the cleaved form of the 
BCL2L15 protein to induce apoptosis is dependent on 
the presence of the BAX or BAK1 (BAK). 
Furthermore, co-expression of the antiapoptotic 
BCL2L1 long isoform (BCLXL) or BCL2L2 (BCLW) 
antagonizes efficiently the killing activity of truncated 
BCL2L15 (Ozören et al., 2009). 
On the other hand, it has been proposed that the 
proapoptotic role of BCL2L15 may resemble more that
of BAX and BAK1 (BAK) than that of BH3-only 
proteins, since it most probably has a structure similar  
to that of BCL2 and BAX. In fact, the position of BH3 
and BH2 domains in the BCL2L15 protein is conserved 
relative to BAX and BCL2 (Coultas et al., 2003). 
Potential phosphorylation at Ser-96 and/or Ser-42 as 
well as other post-translational modifications of 
BCL2L15 might change its subcellular localization and 
further regulate its physiological function (Dempsey et 
al., 2005; Pujianto et al., 2007). 
Homology 
Human BCL2L15 shares 71% amino acid identity and 
80% similarity with the mouse ortholog. BCL2L15 
bears the same combination of BCL2-homology 
domains (BH2 and BH3) as the BCL2L14 long isoform 
(BCLGL) and BCL2L12 full-length isoform, thus 
lacking other domains that are common among BCL2 
family members (BH1 and BH4) or a hydrophobic tail 
(Youle and Strasser, 2008). 
Mutations 
Note 
A single nucleotide polymorphism (SNP) has been 
detected in the coding sequence (GAC→AAC) of the 
BCL2L15 gene, which results in the substitution of an 
amino acid residue bearing a negatively charged side
chain by an amino acid with a polar uncharged side 
chain (D→N). 
Implicated in 
Gastrointestinal cancer, particularly 
colorectal carcinoma 
Prognosis 
BCL2L15 mRNA expression is clearly reduced in a 
wide range of gastrointestinal malignancies. BCL2L15 
mRNA levels are lower in colon tumors, compared to 
levels detected in matched normal colon tissue. 
Moreover, BCL2L15 mRNA expression is significantly 
downregulated in tumors of the small intestine, 
stomach and rectum. This reduction of BCL2L15 
mRNA levels in gastrointestinal neoplasms implies that 
BCL2L15 may contribute to the protective effect of 
proapoptotic BCL2 family proteins against malignant 
transformation of the gastrointestinal tract (Dempsey et 
al., 2005). 
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